Navigation Links
Octapharma Accepting Applications for Research Grants Through March 31

LACHEN, Switzerland and HOBOKEN, N.J., Feb. 4 /PRNewswire/ -- Octapharma USA will accept applications until March 31 for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy, intensive care and emergency medicine. Applications will be reviewed in April.

Octapharma AG, one of the largest plasma products manufacturers in the world, launched the grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's rapidly-growing U.S. subsidiary.

"The grants program has been very well-received and we expect to be announcing our first recipient shortly," said Octapharma USA President Flemming Nielsen. "The U.S. market is very important to Octapharma and the grants program is just one way that we demonstrate our commitment. Our vision of providing patients with the safest, highest quality products available is stronger than ever."

Grant applications are accepted online only at  All grant requests will be evaluated by the Octapharma Grants Committee in April and grant recipients will be announced shortly afterward. Please visit for a complete description of the grants program, including the application and review process.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest plasma products manufacturers in the world and has been committed to patient care and medical innovation for over 25 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD) and granted orphan drug exclusivity. Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit

SOURCE Octapharma USA



SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market
2. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
3. CCMC Accepting Applications for Voluntary Service on its Board of Commissioners
4. Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery
5. Sleep HealthCenters Now Accepting Students for A-STEP Sleep Technologist Program
6. Lupus Foundation of America Accepting Letters of Intent for Research Grants on Adult Stem Cell Research and Health-Related Quality of Life in Pediatric Lupus
7. Nielsen Announces First-Ever CLIO Healthcare Awards Now Accepting Entries
8. ASTRO Accepting Survivor Circle Grant Applications
9. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
10. CCMC Accepting Applications for Second Annual Patricia McCollom Scholarship Through Aug. 1
11. Pittsburgh Day Spa Welcomes Dermatologist, Ana C. Busquets, MD, FAAD And Is Accepting New Patients In Upper St. Clair And Cranberry Locations
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: